Phaseline

Companies › Aptevo Therapeutics

Aptevo Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APVO436
CD123-targeting bispecific T-cell engager (BiTE)
IL3RAPhase 1Acute Myeloid Leukemia (AML)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06634394APVO436Phase 1Acute Myeloid Leukemia (AML)OncologyOct 2027

From the company's SEC filings

Cash of $10m on 2026-06-30; operating cash outflow about $27m a year; runway about 4 months at that burn, to Nov 2026

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

IL3RA (1)

Companies with the same targets

AbbVie Orum Therapeutics USA Stemline Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.